ORL-1拮抗剂1-[(3R,4R)-1-环辛基甲基-3-羟甲基-4-哌啶基]-3-乙基-1,3-二氢-2H-苯并咪唑-2-酮（J-113397）的新合成方法及其在钙动员试验中的活性。
A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay.
作者信息
Smith Emilie D, Ariane Vinson N, Zhong Desong, Berrang Bertold D, Catanzaro Jennifer L, Thomas James B, Navarro Hernán A, Gilmour Brian P, Deschamps Jeffrey, Carroll F Ivy
机构信息
Organic and Medicinal Chemistry, Research Triangle Institute, PO Box 12194, Research Triangle Park, NC 27709, USA.
出版信息
Bioorg Med Chem. 2008 Jan 15;16(2):822-9. doi: 10.1016/j.bmc.2007.10.023. Epub 2007 Oct 13.
Abstract
A new chiral synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (2, J-113397) was developed. J-113397 has a K(e)=0.85nM in an ORL-1 calcium mobilization assay and is 89-, 887-, and 227-fold selective for the ORL-1 receptor relative to the mu, delta, and kappa opioid receptors.
摘要
开发了一种新型手性合成的ORL-1拮抗剂1-[(3R,4R)-1-环辛基甲基-3-羟甲基-4-哌啶基]-3-乙基-1,3-二氢-2H-苯并咪唑-2-酮（2，J-113397）。在ORL-1钙动员试验中，J-113397的K(e)=0.85nM，相对于μ、δ和κ阿片受体，对ORL-1受体的选择性分别为89倍、887倍和227倍。
相似文献
1
A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay.ORL-1拮抗剂1-[(3R,4R)-1-环辛基甲基-3-羟甲基-4-哌啶基]-3-乙基-1,3-二氢-2H-苯并咪唑-2-酮（J-113397）的新合成方法及其在钙动员试验中的活性。
Bioorg Med Chem. 2008 Jan 15;16(2):822-9. doi: 10.1016/j.bmc.2007.10.023. Epub 2007 Oct 13.
2
A new synthetic approach to 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-benzimidazol-2-one(J-113397), the first non-peptide ORL-1 receptor antagonist.一种合成1-[(3R,4R)-1-环辛基甲基-3-羟甲基-4-哌啶基]-3-乙基-1,3-二氢苯并咪唑-2-酮（J-113397）的新方法，它是首个非肽类ORL-1受体拮抗剂。
Bioorg Med Chem. 2001 Jul;9(7):1871-7. doi: 10.1016/s0968-0896(01)00085-2.
3
Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).首个强效且选择性的小分子阿片受体样（ORL1）拮抗剂的发现：1-[(3R,4R)-1-环辛基甲基-3-羟甲基-4-哌啶基]-3-乙基-1,3-二氢-2H-苯并咪唑-2-酮（J-113397）。
J Med Chem. 1999 Dec 16;42(25):5061-3. doi: 10.1021/jm990517p.
4
A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397.一种强效且高度选择性的非肽类孤啡肽/孤啡肽FQ受体（ORL1）拮抗剂：J-113397。
Eur J Pharmacol. 2000 Jan 17;387(3):R17-8. doi: 10.1016/s0014-2999(99)00822-5.
5
In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist.强效选择性非肽类ORL1受体拮抗剂J-113397的体外和体内药理学特性
Eur J Pharmacol. 2000 Aug 18;402(1-2):45-53. doi: 10.1016/s0014-2999(00)00520-3.
6
Quantitative Signaling and Structure-Activity Analyses Demonstrate Functional Selectivity at the Nociceptin/Orphanin FQ Opioid Receptor.定量信号传导与构效关系分析表明孤啡肽/孤啡肽FQ阿片受体存在功能选择性。
Mol Pharmacol. 2015 Sep;88(3):502-11. doi: 10.1124/mol.115.099150. Epub 2015 Jul 1.
7
Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.首个对μ、δ、κ和孤啡肽阿片受体具有纳摩尔亲和力的小分子阿片类全拮抗剂的发现。
ACS Chem Neurosci. 2015 Apr 15;6(4):646-57. doi: 10.1021/cn500367b. Epub 2015 Feb 18.
8
Synthesis and evaluation of 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-[11C]ethyl-1,3-dihydro-2H-benzimidazol-2-one as a brain ORL1 receptor imaging agent for positron emission tomography.1-[(3R,4R)-1-环辛基甲基-3-羟甲基-4-哌啶基]-3-[¹¹C]乙基-1,3-二氢-2H-苯并咪唑-2-酮作为正电子发射断层显像脑ORL1受体显像剂的合成与评价
Nucl Med Biol. 2003 Jan;30(1):51-9. doi: 10.1016/s0969-8051(02)00352-9.
9
In vitro inhibitory effects of J-113397 on nociceptin/orphanin FQ-stimulated.J-113397对孤啡肽刺激的体外抑制作用。
Neuroreport. 2001 Jun 13;12(8):1757-61. doi: 10.1097/00001756-200106130-00048.
10
The opioid receptor like-1 receptor agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one) produces a discriminative stimulus in rats distinct from that of a mu, kappa, and delta opioid receptor agonist cue.阿片样物质受体样-1受体激动剂Ro 64-6198（1S,3aS-8-2,3,3a,4,5,6-六氢-1H-菲-1-基-1-苯基-1,3,8-三氮杂螺[4.5]癸烷-4-酮）在大鼠中产生一种与μ、κ和δ阿片样物质受体激动剂线索不同的辨别性刺激。
J Pharmacol Exp Ther. 2004 Nov;311(2):652-8. doi: 10.1124/jpet.104.071423. Epub 2004 Jun 29.
引用本文的文献
1
Lansoprazole-Based Colorimetric Chemosensor for Efficient Binding and Sensing of Carbonate Ion: Spectroscopy and DFT Studies.基于兰索拉唑的比色化学传感器用于碳酸根离子的高效结合与传感：光谱学和密度泛函理论研究
Front Chem. 2021 Feb 2;8:626472. doi: 10.3389/fchem.2020.626472. eCollection 2020.
2
Optimisation by Design of Experiment of Benzimidazol-2-One Synthesis under Flow Conditions.在流动条件下通过实验设计优化苯并咪唑-2-酮的合成。
Molecules. 2019 Jul 3;24(13):2447. doi: 10.3390/molecules24132447.
3
In silico study of the structurally similar ORL1 receptor agonist and antagonist pairs reveal possible mechanism of receptor activation.计算机模拟研究结构相似的 ORL1 受体激动剂和拮抗剂对，揭示受体激活的可能机制。
Protein J. 2014 Jun;33(3):231-42. doi: 10.1007/s10930-014-9555-0.
4
Ammonium [(1S)-(endo,anti)]-(-)-3-bromo-camphor-8-sulfonate.[(1S)-(内型,反式)]-(-)-3-溴樟脑-8-磺酸铵
Acta Crystallogr Sect E Struct Rep Online. 2010 Jun 18;66(Pt 7):o1707-8. doi: 10.1107/S1600536810022804.
本文引用的文献
1
Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.孤啡肽/痛敏肽受体：药理学及临床意义
Curr Drug Targets. 2007 Jan;8(1):117-35. doi: 10.2174/138945007779315605.
2
N-substituted 4beta-methyl-5-(3-hydroxyphenyl)-7alpha-amidomorphans are potent, selective kappa opioid receptor antagonists.N-取代的4β-甲基-5-（3-羟基苯基）-7α-酰胺基吗啡喃是强效、选择性κ阿片受体拮抗剂。
J Med Chem. 2006 Mar 9;49(5):1781-91. doi: 10.1021/jm058264p.
3
Nociceptin/orphanin FQ modulates spatial learning via ORL-1 receptors in the dorsal hippocampus of the rat.痛敏肽/孤啡肽通过大鼠背侧海马体中的阿片受体样1受体调节空间学习。
Brain Res. 2004 Feb 6;997(2):222-33. doi: 10.1016/j.brainres.2003.11.008.
4
A new synthetic approach to 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-benzimidazol-2-one(J-113397), the first non-peptide ORL-1 receptor antagonist.一种合成1-[(3R,4R)-1-环辛基甲基-3-羟甲基-4-哌啶基]-3-乙基-1,3-二氢苯并咪唑-2-酮（J-113397）的新方法，它是首个非肽类ORL-1受体拮抗剂。
Bioorg Med Chem. 2001 Jul;9(7):1871-7. doi: 10.1016/s0968-0896(01)00085-2.
5
The opioid-receptor-like 1 (ORL-1) as a potential target for new analgesics.
Eur J Med Chem. 2000 Mar;35(3):275-82. doi: 10.1016/s0223-5234(00)00126-4.
6
A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397.一种强效且高度选择性的非肽类孤啡肽/孤啡肽FQ受体（ORL1）拮抗剂：J-113397。
Eur J Pharmacol. 2000 Jan 17;387(3):R17-8. doi: 10.1016/s0014-2999(99)00822-5.
7
Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).首个强效且选择性的小分子阿片受体样（ORL1）拮抗剂的发现：1-[(3R,4R)-1-环辛基甲基-3-羟甲基-4-哌啶基]-3-乙基-1,3-二氢-2H-苯并咪唑-2-酮（J-113397）。
J Med Chem. 1999 Dec 16;42(25):5061-3. doi: 10.1021/jm990517p.
8
Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors.缺乏孤啡肽受体的小鼠中长时程增强和记忆的促进作用。
Nature. 1998 Aug 6;394(6693):577-81. doi: 10.1038/29073.
9
Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress.孤啡肽作为一种抗焦虑剂，可减轻对应激的行为反应。
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14854-8. doi: 10.1073/pnas.94.26.14854.
10
Orphanin FQ inhibits synaptic transmission and long-term potentiation in rat hippocampus.孤啡肽抑制大鼠海马体中的突触传递和长时程增强。
Hippocampus. 1997;7(1):88-94. doi: 10.1002/(SICI)1098-1063(1997)7:1<88::AID-HIPO9>3.0.CO;2-3.
Zotero 插件